Overview

Doxazosin for Psychostimulant Dependence

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder. Thus, the investigators wish to study whether a blood pressure drug thought to reduce drug craving through its interaction at particular adrenergic receptors - doxazosin - can dredge cocaine use relative to placebo in psychostimulant dependent participants enrolled in an 8-week, randomized, double blind, placebo-controlled outpatient clinical trial. Our hypothesis is that doxazosin will reduce cocaine use relative to placebo in psychostimulant dependent participants.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Arkansas
Collaborators:
Baylor College of Medicine
National Institute on Drug Abuse (NIDA)
Treatments:
Doxazosin